Related references
Note: Only part of the references are listed.Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.
Jessica Cecile Hassel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Intermittent Versus Continuous Dosing of MAPK Inhibitors in Treatment of BRAF-Mutated Melanoma
Coralie Reger de Moura et al.
TRANSLATIONAL ONCOLOGY (2020)
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
Elizabeth Iannotti Buchbinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Uveal melanoma
Martine J. Jager et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi et al.
NATURE MEDICINE (2020)
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
Hyejin Choi et al.
CELL REPORTS (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi et al.
ANNALS OF ONCOLOGY (2019)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Sathana Dushyanthen et al.
NATURE COMMUNICATIONS (2017)
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Amanda R. Moore et al.
NATURE GENETICS (2016)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Margaret K. Callahan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.
Sophie Piperno-Neumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Intermittent vemurafenib prevents resistance in melanoma
Nature Reviews Clinical Oncology (2013)
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
Grazia Ambrosini et al.
CLINICAL CANCER RESEARCH (2012)
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Share Paper
